Current Editions
Two mechanisms vie to deliver first hypoxic ischemic encephalopathy drug
ReAlta aims to shut down a pathological cascade, while Pharmazz seeks to restart a developmental program
Product Development
Data Byte
Mounjaro overtakes Keytruda for the first time
Lilly’s diabetes brand alone outsold Keytruda in 1Q26, while combined tirzepatide sales topped the cancer drug by nearly $5B in FY25
Deals
Angelini builds U.S. commercial ops via $4.1B Catalyst acquisition
Italian pharma adds drugs for rare neurological diseases, sales infrastructure
Finance
CellCentric syndicate expands ahead of Phase III myeloma push: Venture Report
Plus: Blackstone backs pancreatic insufficiency play Anagram; Banyan raises new fund; and more
BioCentury ISSN 1097-7201